Group 1 - The company is revising its articles of association, which requires approval from the shareholders' meeting and authorization for related registration procedures [1][2] - The revised governance systems have been approved by the company's board and supervisory board, with some requiring further approval from the shareholders' meeting [2][3] Group 2 - The company held an employee representative meeting on August 6, 2025, to elect Dong Wenkun as the employee representative director for the third board, whose term aligns with the new board [3][4] - Dong Wenkun has a background in pharmaceutical engineering and has held various positions within the company, including director of research and development [4][5] - As of the announcement date, Dong Wenkun does not directly hold company shares but has indirect holdings through a partnership, and he meets all legal qualifications for the position [5]

Group 1 - The company is undergoing a board re-election process as the term of the second board is about to expire, with the third board candidates being nominated [1][2][3] - The candidates for the third board include three non-independent directors and three independent directors, with the independent candidates requiring approval from the Shanghai Stock Exchange before being submitted to the shareholders' meeting [2][3] - The new board members will serve a term of three years starting from the date of approval by the shareholders' meeting [2][3] Group 2 - The second board members have been diligent and contributed positively to the company's operations during their tenure [3] - The company will continue to operate under the current board until the new board is approved by the shareholders [3] Group 3 - The company plans to use up to RMB 4 billion of temporarily idle funds for cash management, focusing on safe and liquid investment products [21][25] - The cash management aims to improve fund utilization efficiency and increase returns while ensuring the company's normal operations and fund safety [23][31] - The board and supervisory committee have approved this cash management plan, which will be submitted for shareholder approval [32][33] Group 4 - The company is proposing to cancel its supervisory board and transfer its responsibilities to the audit committee of the board, in line with recent regulatory changes [78][79] - The company will revise its articles of association to reflect these changes, including the removal of references to the supervisory board [78][81]

风险提示：股市有风险，投资需谨慎。 8月6日晚间，安旭生物发布多份公告。公司第二届董事会第十八次会议审议通过了董事会换届选举等多 项议案。同时，公司将于8月22日召开2025年第一次临时股东大会，审议取消监事会等议案。此外，公 司拟使用不超过40亿元闲置自有资金进行现金管理，该议案尚需股东大会审议通过。 资金流向方面，8月6日安旭生物主力资金净流出379.91万元，近五个交易日累计净流出126.40万元。 安旭生物8月6日报收42.29元，较前一交易日下跌0.37元，跌幅0.87%。当日成交量为12289手，成交金 额达0.53亿元。该股开盘报42.66元，盘中最高触及43.99元，最低下探42.10元，振幅4.43%。 安旭生物属于医疗器械行业，专注于体外诊断产品的研发、生产和销售。公司产品涵盖传染病检测、毒 品检测、妊娠检测等多个领域，业务范围涉及全球多个国家和地区。 ...

（文章来源：证券日报） 证券日报网讯 8月6日晚间，安旭生物发布公告称，公司第二届监事会第十六次会议审议通过了《关于 取消监事会、修订并办理工商变更登记及修订相关制度的议案》等多项议案。 ...

（文章来源：证券日报） 证券日报网讯 8月6日晚间，安旭生物发布公告称，公司第二届董事会第十八次会议审议通过了《关于 董事会换届选举暨提名第三届董事会非独立董事候选人的议案》等多项议案。 ...

Group 1 - The company announced the organization of a staff representative meeting on August 6, 2025, to elect Mr. Dong Wenkun as the employee representative director of the third board of directors [2] - Mr. Dong Wenkun's term will be consistent with that of the company's third board of directors [2]

证券日报网讯 8月6日晚间，安旭生物发布公告称，公司于2025年8月6日召开第二届董事会第十八次会 议和第二届监事会第十六次会议，审议通过了《关于使用部分暂时闲置自有资金进行现金管理的议 案》，同意公司在保证公司正常经营运作资金需求和资金安全的前提下，使用不超过人民币400， 000.00万元的部分暂时闲置自有资金进行现金管理。本事项尚需提交公司2025年第一次临时股东大会审 议。有效期自2025年9月18日起12个月内有效。在上述额度及期限内，资金可以循环滚动使用。 （文章来源：证券日报） ...

Group 1 - Xianhe Co., Ltd. plans to invest approximately 11 billion yuan in an integrated high-performance paper-based material project in Sichuan Province, with an expected annual production capacity of 800,000 tons of bamboo pulp and 1.2 million tons of high-performance paper-based materials [1] - Funi Co., Ltd. intends to invest about 7.802 billion yuan in the construction of a pumped storage power station project in Nanan, Fujian Province, which will enhance the company's clean energy capacity [6] - Zhongchuan Technology's subsidiary plans to invest approximately 5.712 billion yuan in a 1.3 million kilowatt wind power project in Xinjiang [9] Group 2 - Shennong Group reported a sales revenue of 327 million yuan from the sale of 174,700 pigs in July 2025, with an average selling price of 14.73 yuan per kilogram, reflecting a 2.65% increase from June 2025 [2] - CITIC Securities' subsidiary, Huaxia Fund, achieved a net profit of 1.123 billion yuan in the first half of 2025, with total assets under management reaching 2.8512 trillion yuan [5] - Jiangnan Water Affairs plans to publicly transfer an 8% stake in Pudong Village Bank, with a minimum transfer price of approximately 12.548 million yuan [4] Group 3 - Anxu Bio plans to utilize up to 4 billion yuan of temporarily idle funds for cash management [8] - Changsheng Bearing has set the inquiry transfer price at 61.82 yuan per share for its upcoming share transfer [11] - Electric Connection Technology intends to acquire a 39% stake in its subsidiary, Aimers, for 180 million yuan, increasing its ownership from 51% to 90% [12]

证券代码：688075 证券简称：安旭生物 公告编号：2025-017 杭州安旭生物科技股份有限公司 关于董事会换届选举的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 杭州安旭生物科技股份有限公司（以下简称"公司"或"安旭生物"）第二届董事 会任期即将届满。根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《上海证券交易所科创板股票上市规则》等法律、法规以及《公司章程》等相关规 定，公司开展董事会换届选举工作，现将具体情况公告如下： 一、 董事会换届选举情况 换届选举暨提名第三届董事会非独立董事候选人的议案》和《关于董事会换届选举 暨提名第三届董事会独立董事候选人的议案》。 经公司董事会提名委员会对公司第三届董事会董事候选人的任职资格审查，董 事会同意提名凌世生先生、姜学英女士、黄银钱先生为公司第三届董事会非独立董 事候选人；同意提名戴文涛先生、宋达峰先生、程乐先生为公司第三届董事会独立 董事候选人，其中戴文涛先生为会计专业人士。上述董事候选人经公司股东大会审 议通过后，将与经公司职工代表大会选举产生的 1 ...

证券代码：688075 证券简称：安旭生物 公告编号：2025-017 杭州安旭生物科技股份有限公司 关于董事会换届选举的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 杭州安旭生物科技股份有限公司（以下简称"公司"或"安旭生物"）第二届董事 会任期即将届满。根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《上海证券交易所科创板股票上市规则》等法律、法规以及《公司章程》等相关规 定，公司开展董事会换届选举工作，现将具体情况公告如下： 一、董事会换届选举情况 2025 年 8 月 6 日，公司第二届董事会第十八次会议审议通过了《关于董事会 换届选举暨提名第三届董事会非独立董事候选人的议案》和《关于董事会换届选举 暨提名第三届董事会独立董事候选人的议案》。 经公司董事会提名委员会对公司第三届董事会董事候选人的任职资格审查，董 事会同意提名凌世生先生、姜学英女士、黄银钱先生为公司第三届董事会非独立董 事候选人；同意提名戴文涛先生、宋达峰先生、程乐先生为公司第三届董事会独立 董事候选人，其中戴文涛先生为会计专业人士 ...